A genomic profile is more than just a test. Our assays provide biomarker information to help match patients to approved targeted therapies, immunotherapies, and clinical trials — giving doctors and patients powerful actionable insights for navigating cancer care.
Uncovering More Options for Each Unique Cancer
Each cancer is unique and each tumor can vary at the molecular level. A single genomic test can reveal alterations in DNA that drive cancer growth to help identify personalized treatment options based on a tumor’s unique genomic profile.
Next-Generation Sequencing (NGS) is used to analyze cancer specimens for all four classes of genomic alterations (base substitutions, insertions and deletions, copy number alterations, and rearrangements) known to be relevant in solid tumors, sarcomas, and hematologic malignancies.
Getting a Foundation Medicine Test
- Physician and patient discuss testing options together.
- Physician orders the appropriate test.
- Physician collects a tissue, blood, or bone marrow sample from patient.
- Physician sends sample to the Foundation Medicine laboratory.
- Physician receives online and printed results typically within 2 weeks from receipt of sample at Foundation Medicine.
- Physician and patient discuss results and potential treatment options.
Compare Foundation Tests
Our Diagnostic Portfolio
- Sample Type
- Tumor Mutational Burden (TMB)*
- Microsatellite instability (MSI)*
- FoundationOne CDx™
- All Solid Tumors
- Details →
- Lung, GI, Breast, and other solid tumors
- Peripheral Whole Blood
- Details →
- Leukemias, lymphomas, or sarcomas
- FFPE, Peripheral Whole Blood, Bone Marrow Aspirate
- Details →
Cancer Immunotherapy Biomarkers
Helping Predict Response with Tumor Mutational Burden
Cancer immunotherapies have the potential to treat cancer by harnessing the power of our own immune systems. But right now, only about 20-40% of people respond to this important class of therapy.1,2 Learn about a quantitative clinical biomarker, tumor mutational burden (TMB), that can help identify patients who may be more likely to benefit from cancer immunotherapies.3
Frequently Asked Questions
- What services does Foundation Medicine offer for biopharmaceutical companies?
- How can genomic data generated by Foundation Medicine assays be used for biomarker discovery?
- What are the specifications of Foundation Medicine’s FoundationCore™ database?
- How do I contact someone in the biopharma group to discuss a project?
Results & Reporting
Test results are provided directly to physicians in a report that highlights the genomic alterations in a patient’s cancer and includes information to help inform treatment decisions. Everything in the report is supported by up-to-date clinical findings and scientific research. Patients may request a copy of their report by contacting Client Services.
- Genomic Alterations
Information about identified genomic alterations of all types and interpretation of results.
List of available therapies relevant for the genomic alterations identified.
- Clinical Trials
Clinical trials that the patient may be eligible for and guidance for the physician on identifying additional trials in public databases.
Additional information such as the full list of genes assayed, variants of unknown significance, technical information, and references.
Track Orders and View Patient Reports Online or On Your Phone
A patient with cancer should not have to worry about the affordability of testing. That’s why we offer the FoundationAccess financial assistance program.
Financial Assistance Program
Our financial assistance program provides patients with the opportunity for comprehensive genomic profiling, regardless of financial status. We also offer direct support and guidance during each step of the billing process.
We're committed to excellent service. If you have questions or need assistance, our client services team is on-hand to help.
Need More Details?
* Tumor Mutational Burden is a validated clinical marker associated with response to immunotherapy.
1 Márquez-Rodas et al. Immune checkpoint inhibitors: therapeutic advances in melanoma. Ann Transl Med. 2015 October;3(18):267.
2 Wolchok et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013 July 11;369(2):122-33.
3 Goodman AM, et al. Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 Nov;16(11):2598-2608.